3 Drug Stocks Making Huge Moves

Upbeat drug data is lifting GTx

Mar 5, 2018 at 3:01 PM
facebook X logo linkedin


The Nasdaq is surging higher today, thanks to another strong showing for healthcare stocks. Three names in particular making notable moves are Atara Biotherapeutics Inc (NASDAQ:ATRA), GTx, Inc. (NASDAQ:GTXI), and Dermira Inc (NASDAQ:DERM) Let's take a closer look at what's moving shares of ATRA, GTXI, and DERM.

Jefferies Thinks Atara Can Deliver On MS Drug

Atara Biotherapeutics stock is trading 9.3% higher at $43.05, after Jefferies analyst Maury Raycroft said "there is a chance for success" for the company's multiple sclerosis treatment. Raycroft lifted his price target to $46 from $30 for ATRA stock, though this offers little upside from its current perch. In fact, the shares peaked at a two-year high of $49.90 back on Feb. 14. Overall, the equity has surged 138% year-to-date.

Despite this, short interest remains near its mid-June record high. More than one-third of ATRA's float is sold short, equaling a week's worth of buying power, going by average daily volumes.

Drug Data Boosts GTXI Stock

Positive mid-stage trial results for GTx's stress urinary incontinence drug, enobosarm, has the stock up 31% at $22, with the shares earlier tapping a four-year high of $22.89. It's been an incredible run up the carts for GTXI, which has exploded higher since its early June annual lows below $3. Plus, today's breakout earned GTXI shares price-target hikes to $20 at Baird and to $45 at Stifel.

DERM Stock Demolished After Trial Fails

Mizuho downgraded Dermira stock to "neutral" from "buy," and slashed its price target to $9 from $39. Cowen also cut its price target -- to $25 from $55 -- after the company's acne treatment failed two late-stage studies. Dermira is discontinuing development of the drug as a result. DERM shares were last seen 64% lower at $9.05, hitting a record low of $8.95 earlier. Even with the stock short-sale restricted today, short sellers have to be celebrating. These bearish bets increased by 12% over the past two reporting periods, and account for 14.1% of the equity's float.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI